<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01283334</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00040298</org_study_id>
    <secondary_id>WCI1761-09</secondary_id>
    <nct_id>NCT01283334</nct_id>
  </id_info>
  <brief_title>A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase I/IIB Study of Combination Weekly Carboplatin, Cetuximab and Dose Escalation of RAD001 in Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the drug RAD001 in combination with other chemotherapy&#xD;
      drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination&#xD;
      before, it is not clear which dose will be best when used in combination.&#xD;
&#xD;
      The investigators will test the safety of RAD001 in combination with Carboplatin and&#xD;
      Cetuximab and see what effects (good and/or bad) it has on your cancer, and find the highest&#xD;
      dose of RAD001 that can be given without causing bad side effects. The doses of Carboplatin&#xD;
      and Cetuximab will not be varied as both these drugs are considered to be part of the current&#xD;
      standard of care for patients with your condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer</measure>
    <time_frame>Within the first 21 days of therapy</time_frame>
    <description>This phase 1 clinical trial used a standard 3 + 3 design. Four dose levels of everolimus were planned to be evaluated, and the standard 3 + 3 design with dose de-escalation was used in the trial. Namely, 3 patients were assigned to starting dose level 1. If no dose-limiting toxicity (DLT) was observed, the trial proceeded to the next dose level, and another cohort of 3 patients was enrolled. If at least 2 of the 3 patients experienced at least 1 DLT, then the dose level decreased; otherwise, if only 1 patient experienced DLT, then 3 more patients were enrolled at the same dose level. If none of the 3 additional patients experienced DLT, the dose was escalated; otherwise, the dose level decreased. Dose reduction continued until a dose level was reached at which 6 patients had been treated and at most 1 DLT was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>The time of PFS was calculated as the time from study enrollment to the disease progression date, death date, or last contact, whichever came first, up to 25 months</time_frame>
    <description>Objective tumor responses were assessed every 2 cycles of chemotherapy with computed tomography or positron emission tomography/ computed tomography scans in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Cancer of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm with carboplatin, cetuximab and RAD001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Everolimus</other_name>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have at least one measurable site of disease according to Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously&#xD;
             irradiated. If the patient has had previous radiation to the marker lesion(s), there&#xD;
             must be evidence of progression since the radiation.&#xD;
&#xD;
          -  Histologically or cytologically proven squamous cell carcinoma of the head and neck&#xD;
             (SCCHN).&#xD;
&#xD;
          -  Patients with recurrent, refractory or metastatic squamous cell carcinoma of oral&#xD;
             cavity, oropharynx and larynx, hypopharynx or paranasal sinus, and unknown primary&#xD;
             SCCHN who failed to respond to, or relapsed from prior chemoradiotherapy for&#xD;
             definitive treatment of disease.&#xD;
&#xD;
          -  Evaluable locoregional and/or metastatic disease according to RECIST criteria (see&#xD;
             Section 6) that is not appropriate for treatment by primary surgical resection or&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Patients may not have had prior chemotherapy for recurrent or metastatic disease.&#xD;
&#xD;
          -  Patients must not be candidates for curative therapy.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.&#xD;
&#xD;
          -  Life expectancy of ≥ 4 months.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following:&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0/dl&#xD;
&#xD;
               -  Absolute-neutrophil count (ANC ) ≥ 1500/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN&#xD;
                  (≤ 5 x ULN for patients with liver involvement)&#xD;
&#xD;
               -  International normalized ratio (INR) ≤ 1.5 or a prothrombin time (PT) and partial&#xD;
                  thromboplastin time (PTT) within normal limits (Anticoagulation is allowed if&#xD;
                  target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of low&#xD;
                  molecular weight (LMW) heparin for &gt; 2 weeks at time of randomization)&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5&#xD;
             x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can&#xD;
             only be included after initiation of appropriate lipid lowering medication.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to first receiving investigational product. Sexually active women of&#xD;
             childbearing potential (WOCBP) must use an effective method of birth control during&#xD;
             the course of the study, in a manner such that risk of failure is minimized. Prior to&#xD;
             study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during&#xD;
             trial participation and the potential risk factors for an unintentional pregnancy. In&#xD;
             addition, men enrolled on this study should understand the risks to any sexual partner&#xD;
             of childbearing potential and should practice an effective method of birth control.&#xD;
             All WOCBP should be instructed to contact the Investigator immediately if they suspect&#xD;
             they might be pregnant (e.g., missed or late menstrual period) at any time during&#xD;
             study participation.&#xD;
&#xD;
          -  Signed informed consent prior to beginning protocol specific procedures. Voluntary&#xD;
             written informed consent before performance of any study-related procedure not part of&#xD;
             normal medical care, with the understanding that consent may be withdrawn by the&#xD;
             subject at any time without prejudice to future medical care. Patients or their legal&#xD;
             representatives must be able to read, understand and provide informed consent to&#xD;
             participate in the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of prior malignancy within the past 5 years except for curatively treated&#xD;
             basal cell carcinoma and squamous cell carcinoma of the skin, cervical intraepithelial&#xD;
             neoplasia (CIN) or localized prostate cancer with a current prostate-specific antigen&#xD;
             (PSA) &lt; 1.0 mg/dL on 2 successive evaluations at least 3 months apart, with the most&#xD;
             recent evaluation within 4 weeks of study entry.&#xD;
&#xD;
          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to&#xD;
             require glucocorticoids for brain or leptomeningeal metastases. Patients with&#xD;
             neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain&#xD;
             metastasis.&#xD;
&#xD;
          -  Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 4 weeks of the start of study drug (including chemotherapy, radiation&#xD;
             therapy, antibody based therapy, etc.).&#xD;
&#xD;
          -  Prior treatment with any investigational drug within the preceding 4 weeks.&#xD;
&#xD;
          -  Any unresolved toxicity (except alopecia) greater than NCI-Common Toxicity Criteria&#xD;
             for Adverse Effects (CTCAE) v3.0 grade 2 from prior systemic anticancer therapy.&#xD;
&#xD;
          -  Patients who have received prior treatment with a mammalian target of rapamycin (mTOR)&#xD;
             inhibitor (sirolimus, temsirolimus, everolimus).&#xD;
&#xD;
          -  Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins&#xD;
             (sirolimus, temsirolimus) or to its excipients, or to cetuximab.&#xD;
&#xD;
          -  Prior therapy with Cetuximab will be allowed provided it was part of definitive&#xD;
             therapy and not part of treatment for recurrent or metastatic disease.&#xD;
&#xD;
          -  Prior severe infusion reaction to a monoclonal antibody.&#xD;
&#xD;
          -  Patients receiving chronic, systemic treatment with corticosteroids or another&#xD;
             immunosuppressive agent. Topical or inhaled corticosteroids are allowed.&#xD;
&#xD;
          -  Patients should not receive immunization with attenuated live vaccines within one week&#xD;
             of study entry or during study period.&#xD;
&#xD;
          -  Patients, who have had a major surgery or significant traumatic injury within 4 weeks&#xD;
             of start of study drug, patients who have not recovered from the side effects of any&#xD;
             major surgery (defined as requiring general anesthesia) or patients that may require&#xD;
             major surgery during the course of the study.&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as:&#xD;
&#xD;
               -  Symptomatic congestive heart failure of New York heart Association Class III or&#xD;
                  IV&#xD;
&#xD;
               -  Unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction within 6 months of start of study drug, serious uncontrolled cardiac&#xD;
                  arrhythmia or any other clinically significant cardiac disease&#xD;
&#xD;
               -  Severely impaired lung function as defined as spirometry and diffusing capacity&#xD;
                  of lung for carbon monoxide (DLCO) that is 50% of the normal predicted value&#xD;
                  and/or 02 saturation that is 88% or less at rest on room air&#xD;
&#xD;
               -  Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 x ULN&#xD;
&#xD;
               -  Active (acute or chronic) or uncontrolled severe infections&#xD;
&#xD;
               -  Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent&#xD;
                  hepatitis&#xD;
&#xD;
          -  Abnormal liver function tests (LFTs) as follows: total bilirubin (TB) &gt; 1.5x ULN,&#xD;
             alanine aminotransferase (ALT) &gt; 1.25x ULN, and/or alkaline phosphatase &gt; 2.5 x ULN&#xD;
             (except when LFTs attributed to metastatic SCCHN, in which case, TB, ALT and alkaline&#xD;
             phosphatase must be ≤ NCI-CTCAE, v3.0 grade 1).&#xD;
&#xD;
          -  Absolute neutrophil count &lt; 1000/mm3 or platelets &lt; 100,000/mm3.&#xD;
&#xD;
          -  A known history of HIV seropositivity.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled&#xD;
             nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).&#xD;
&#xD;
          -  Patients with an active, bleeding diathesis.&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods. If barrier contraceptives&#xD;
             are being used, these must be continued throughout the trial by both sexes. Hormonal&#xD;
             contraceptives are not acceptable as a sole method of contraception. (WOCBP must have&#xD;
             a negative urine or serum pregnancy test within 7 days prior to administration of&#xD;
             RAD001).&#xD;
&#xD;
          -  History of noncompliance to medical regimens.&#xD;
&#xD;
          -  Patients unwilling to or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil F. Saba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, Ramalingam SS, Chen Z, Rogerio J, Mendel J, Kono SA, Lewis C, Chen AY, Higgins K, El-Deiry M, Wadsworth T, Beitler JJ, Shin DM, Sun SY, Khuri FR. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014 Dec 15;120(24):3940-51. doi: 10.1002/cncr.28965. Epub 2014 Aug 7.</citation>
    <PMID>25103371</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>January 24, 2011</study_first_submitted>
  <study_first_submitted_qc>January 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2011</study_first_posted>
  <results_first_submitted>November 17, 2014</results_first_submitted>
  <results_first_submitted_qc>November 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 4, 2014</results_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Nabil F. Saba</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>After institutional review board approval, the study enrolled 20 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Carboplatin, Cetuximab and Everolimus</title>
          <description>Carboplatin, cetuximab and RAD001 (everolimus)&#xD;
Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to Swallow Everolimus Pills</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Carboplatin, Cetuximab and Everolimus</title>
          <description>Carboplatin, cetuximab and RAD001 (everolimus)&#xD;
Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer</title>
        <description>This phase 1 clinical trial used a standard 3 + 3 design. Four dose levels of everolimus were planned to be evaluated, and the standard 3 + 3 design with dose de-escalation was used in the trial. Namely, 3 patients were assigned to starting dose level 1. If no dose-limiting toxicity (DLT) was observed, the trial proceeded to the next dose level, and another cohort of 3 patients was enrolled. If at least 2 of the 3 patients experienced at least 1 DLT, then the dose level decreased; otherwise, if only 1 patient experienced DLT, then 3 more patients were enrolled at the same dose level. If none of the 3 additional patients experienced DLT, the dose was escalated; otherwise, the dose level decreased. Dose reduction continued until a dose level was reached at which 6 patients had been treated and at most 1 DLT was observed.</description>
        <time_frame>Within the first 21 days of therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus Dose Level 1 DLT</title>
            <description>Carboplatin, cetuximab and RAD001 (everolimus) at Dose Level 1 (2.5 mg/day)</description>
          </group>
          <group group_id="O2">
            <title>Everolimus Dose Level -1 DLT</title>
            <description>Carboplatin, cetuximab and RAD001 (everolimus) at Dose Level -1 (2.5 mg every other day)</description>
          </group>
        </group_list>
        <measure>
          <title>To Measure the Safety and Clinical Effectiveness of the Combination of Carboplatin, Cetuximab and RAD001 in Patients With Advanced (Recurrent or Metastatic) Head and Neck Cancer</title>
          <description>This phase 1 clinical trial used a standard 3 + 3 design. Four dose levels of everolimus were planned to be evaluated, and the standard 3 + 3 design with dose de-escalation was used in the trial. Namely, 3 patients were assigned to starting dose level 1. If no dose-limiting toxicity (DLT) was observed, the trial proceeded to the next dose level, and another cohort of 3 patients was enrolled. If at least 2 of the 3 patients experienced at least 1 DLT, then the dose level decreased; otherwise, if only 1 patient experienced DLT, then 3 more patients were enrolled at the same dose level. If none of the 3 additional patients experienced DLT, the dose was escalated; otherwise, the dose level decreased. Dose reduction continued until a dose level was reached at which 6 patients had been treated and at most 1 DLT was observed.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Objective tumor responses were assessed every 2 cycles of chemotherapy with computed tomography or positron emission tomography/ computed tomography scans in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria.</description>
        <time_frame>The time of PFS was calculated as the time from study enrollment to the disease progression date, death date, or last contact, whichever came first, up to 25 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carboplatin, Cetuximab and Everolimus</title>
            <description>Carboplatin, cetuximab and RAD001 (everolimus)&#xD;
Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Objective tumor responses were assessed every 2 cycles of chemotherapy with computed tomography or positron emission tomography/ computed tomography scans in accordance with Response Evaluation Criteria In Solid Tumors (RECIST) criteria.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" lower_limit="1" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 25 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carboplatin, Cetuximab and Everolimus</title>
          <description>Carboplatin, cetuximab and RAD001 (everolimus)&#xD;
Carboplatin, cetuximab and RAD001: For phase I, dose escalation will be 2.5mg, 5mg, 7.5mg or 10mg given orally on a daily basis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <description>Patient admitted to emergency department (ED)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hemoptysis and death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this analysis include the small sample size in this phase 1b study, a patient population with mixed primary sites of disease, and variable doses of everolimus.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nabil F. Saba, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1900</phone>
      <email>nfsaba@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

